Literature DB >> 8999548

Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.

Y Gu1, K Kuida, H Tsutsui, G Ku, K Hsiao, M A Fleming, N Hayashi, K Higashino, H Okamura, K Nakanishi, M Kurimoto, T Tanimoto, R A Flavell, V Sato, M W Harding, D J Livingston, M S Su.   

Abstract

The interleukin-1beta (IL-1beta) converting enzyme (ICE) processes the inactive IL-1beta precursor to the proinflammatory cytokine. ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export. Lipopolysaccharide-activated ICE-deficient (ICE-/-) Kupffer cells synthesized the IGIF precursor but failed to process it into the active form. Interferon-gamma and IGIF were diminished in the sera of ICE-/- mice exposed to Propionibacterium acnes and lipopolysaccharide. The lack of multiple proinflammatory cytokines in ICE-/- mice may account for their protection from septic shock.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8999548     DOI: 10.1126/science.275.5297.206

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  308 in total

1.  Activation of caspase 3 during Legionella pneumophila-induced apoptosis.

Authors:  L Y Gao; Y Abu Kwaik
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  Molecular mechanisms in T helper phenotype development.

Authors:  J D Farrar; S H Ranganath; K M Murphy
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Differential cytokine responses following Marek's disease virus infection of chickens differing in resistance to Marek's disease.

Authors:  Pete Kaiser; Greg Underwood; Fred Davison
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease.

Authors:  Othmar Ludwiczek; Arthur Kaser; Daniela Novick; Charles A Dinarello; Menachem Rubinstein; Wolfgang Vogel; Herbert Tilg
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

5.  Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination.

Authors:  S Hisahara; T Araki; F Sugiyama; K i Yagami; M Suzuki; K Abe; K Yamamura; J Miyazaki; T Momoi; T Saruta; C C Bernard; H Okano; M Miura
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

Review 6.  Interleukin-18 as a potential target in inflammatory arthritis.

Authors:  J A Gracie
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

7.  Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency.

Authors:  Eric P Zorrilla; Manuel Sanchez-Alavez; Shuei Sugama; Molly Brennan; Rosette Fernandez; Tamas Bartfai; Bruno Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

8.  Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates.

Authors:  Vitaliano Cusumano; Angelina Midiri; Valentina Valeria Cusumano; Antonella Bellantoni; Giuseppe De Sossi; Giuseppe Teti; Concetta Beninati; Giuseppe Mancuso
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 9.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

10.  The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques.

Authors:  Mireille Laforge; Ricardo Silvestre; Vasco Rodrigues; Julie Garibal; Laure Campillo-Gimenez; Shahul Mouhamad; Valérie Monceaux; Marie-Christine Cumont; Henintsoa Rabezanahary; Alain Pruvost; Anabela Cordeiro-da-Silva; Bruno Hurtrel; Guido Silvestri; Anna Senik; Jérôme Estaquier
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.